Mnemo Therapeutics

Mnemo Therapeutics is a Paris-based clinical-stage biotechnology company founded in 2019. The company focuses on improving the efficacy of T cell-based cancer immunotherapies — including CAR-T and TCR-T therapies — by applying epigenetic reprogramming techniques to enhance T cell persistence, memory, and anti-tumor activity. Mnemo's platform identifies and modulates the epigenetic regulators that govern T cell fate, aiming to produce immune cells with superior durability in the tumor microenvironment. Headquartered at 101 Boulevard Murat in Paris, the company raised a €75M Series A in 2021 and has conducted research collaborations with the Institut Curie and other academic partners.